Clinical question: What is the most appropriate management of fungal keratitis? Results: Traditionally, topical Natamycin is the most commonly used medication for filamentous fungi while Amphotericin B is most commonly used for yeast. Voriconazole is rapidly becoming the drug of choice for all fungal keratitis because of its wide spectrum of coverage and increased penetration into the cornea. Implementation: Repeated debridement of the ulcer is recommended for the penetration of topical medications. While small, peripheral ulcers may be treated in the community, larger or central ulcers, especially if associated with signs suggestive of anterior chamber penetration should be referred to a tertiary center. Prolonged therapy for approximately four weeks is usually necessary.
Fungal keratitis
Definition: Fungal keratitis (keratomycosis) is a fungal infection of the cornea. It primarily affects the corneal epithelium and stroma, although the endothelium and anterior chamber of the eye may get involved in more severe disease. Incidence: Fungal keratitis is primarily seen in tropical climates and is rare in temperate areas. Its incidence is between 6%-20% of all microbial keratitis cases depending on the geographic location. 1, 2 Traditionally, it is considered a disease of rural areas and is frequently caused by trauma with vegetative material. However, the major risk factor in developed countries is contact lens use at this time. 3 Its incidence has been reported to be increasing due to widespread use of contact lenses, especially bandage contact lenses, and topical steroid usage. 3, 4 While tropical climates show a preponderance of filamentous fungi, temperate climates show higher percentages of yeast infections. 1, 5, 6 Economics: Although no studies evaluating the economic implications of fungal keratitis are available, this is primarily a disease of young, working adults and is becoming more common. These facts, combined with the need for prolonged, intensive treatment and relatively poor visual outcomes, suggest that the adverse economic implications are significant. Level of evidence: Systematic reviews and randomized controlled trials (RCTs). Cohort and observational studies were also reviewed for additional data. There were three systematic reviews that evaluated the medical therapy of fungal keratitis. The Cochrane review 8 in 2008 concluded that there was no evidence that the current available and investigational antifungal agents were effective. The review identified the need for large multicenter randomized trials. However, none of the studies they evaluated used either Amphotericin B or Voriconazole. The Hariprasad et al review 9 evaluated over 40 laboratory studies and clinical case reports of treatment with voriconazole and concluded that it may be used safely and effectively against a broad range of fungal pathogens. In 2000, the O'Day and Head review 10 concluded that although there had been progress in the treatment and outcomes of fungal keratitis, it was painfully slow. This was partly due to the almost total absence of interest in the problem by the pharmaceutical industry. Table 1 shows the various RCTs that compared various antifungal medications to each other in terms of clinical outcomes. However, there was no specific medication that was shown to be superior to the others. Only three studies evaluated the visual outcomes and adverse outcomes between medication and are shown in Table 2 . In addition, there were two laboratory studies; one comparing antifungal medications for aspergillus in rabbits; and candida (isolates from 41 countries) by disk diffusion shown in Table 3 .
Conclusion
As the studies indicate, there is no one good broad spectrum anti-fungal medication that is effective in all cases of fungal keratitis. The initial therapy should be based on the organism suspected. While Natamycin is the only commercially available medication, it has a limited therapeutic spectrum. Voriconazole or Amphotericin B may be better first line drugs in unknown cases as they have broader efficacy. Other medications do not offer any improvement over these drugs and should be reserved for therapeutic failures. The practice
Potential pitfalls
Fungal organisms can penetrate through the corneal stroma without perforation of the cornea resulting in an infectious hypopyon or endothelial plaque. The problem is that the majority of antifungal medications have very poor penetration especially in the face of an intact epithelium. Unlike bacterial keratitis, the corneal epithelium overlying a stromal fungal infection can heal despite the presence of active infection once treatment is initiated and should not, by itself, be used as a guide to successful therapy.
Management
Fungal keratitis should be suspected in cases of keratitis that do not respond to antibacterial agents especially in cases of vegetative trauma or extended wear contact lens usage. These cases should be scraped and sent for KOH or Gomorimethenamine silver stains as well as culture on Saboraud agar.
Assessment
Feathery borders, ring infiltrate, endothelial plaque, fibrinoid aqueous, and satellite lesions should raise the suspicion of fungal keratitis (Figure 1) . Endothelial plaques or an anterior chamber reaction usually indicate a more severe infection with penetration of fungal elements into the anterior chamber ( Figure 2 ). Response to therapy is usually indicated by blunting of the feathery edges, re-epithelialization, or reduction in the anterior chamber reaction.
Treatment
The only commercially available antifungal drug in the United States is Natamycin (also called Pimaricin) available as a 5% suspension. In other parts of the world where keratomycosis is seen much more frequently such as India, additional antifungal agents such as Fluconazole and Miconazole are available. However, various other drugs can be compounded into eye drops (by compounding pharmacies) and are effective. The most commonly used drugs are Voriconazole (1%), 7, 11 Amphotericin B (0.15%), Fluconazole, and Miconazole. Antiseptics such as Chlorhexidine 0.2% and Povidone iodine (5%) have also been advocated as cheap and easily available alternatives but are not as effective. 12 Systemic antifungal medications have been advocated as adjunctive therapy in severe cases, especially ulcers with anterior chamber reaction but there have been no controlled studies showing a clear benefit of adding systemic antifungals. 13, 14 Therapy should be aggressive and most authors advocate dual therapy to avoid the risk of resistance. Typically, the topical antifungals are given every hour initially. The duration of treatment is from 3-4 weeks on average. If efficacy is not noted within a week or there is worsening, consideration should be given to changing the medication to another class or asking the laboratory to run sensitivities on the cultured fungus.
If the infection continues to worsen or there is worsening anterior chamber reaction, surgical management may be indicated. This includes therapeutic keratoplasty and, in severe cases, enucleation may be necessary.
indications for specialist referral
Small, superficial, peripheral ulcers can be managed in the community with a combination of frequent antifungal agents and epithelial debridement every three days. Large, deep, or central ulcers with an endothelial plaque, a hypopyon or fibrinoid aqueous should preferably be referred to a cornea specialist within a day. Paracentral ulcers may be managed in the community if smaller and without evidence of anterior chamber penetration. However, if no response is noted within a week, the physician should consider referring the patient to a specialist.
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